Application for registration of shutaishen new drug "mouse nerve growth factor for injection" has not been approved

Shutaishen (300204) announced in the evening of May 5 that on April 30, the company received the notice of approval opinions from the State Food and drug administration The new drug "rat nerve growth factor for injection" of the company did not meet the relevant requirements of drug registration and did not approve the application for registration of the product The reason is that the data currently provided does not support the clinical trial of the product According to the relevant regulations, the company did not agree with the product To carry out a clinical trial with diabetic peripheral neuropathy as the indication In response, shutaishen said that the increase of indications of diabetic peripheral neuropathy by injecting rat nerve growth factor without the approval of registration application for clinical trial would not affect the company's recent performance Shu Taishen also announced that the company, as a limited partner, will use its own capital of 10 million yuan to participate in the investment in Beijing ChuangJin Xingye Investment Center (limited partnership) The partnership makes equity investment or other investment permitted by law and business scope to entities operating in China to realize capital appreciation In addition, Xiangtang group, the shareholder of the company, reduced 4 million shares of the company through block trading from April 28 to May 4, 2015, accounting for 1.19% of the current total share capital of the company After the reduction, Xiangtang group still holds 23.76% of the company's equity